Aug 14 (Reuters) - Celsion Corp ::ORATION REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q2 LOSS PER SHARE $0.29.Q2 EARNINGS PER SHARE ESTIMATE $-0.32 -- REFINITIV IBES DATA.ENDED Q2 OF 2019 WITH $21.8 MILLION IN CASH, INVESTMENT SECURITIES AND INTEREST RECEIVABLE.
Full Article
May 15 (Reuters) - Celsion Corp ::ORATION REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q1 LOSS PER SHARE $0.12.CASH, CASH EQUIVALENTS, SHORT-TERM INVESTMENTS AND INTEREST RECEIVABLE AT MARCH 31, 2019 WAS $23.8 MILLION.
Full Article
Nov 14 (Reuters) - Celsion Corp ::ORATION REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q3 LOSS PER SHARE $0.26.EXPECTS TO RECEIVE APPROXIMATELY $10 MILLION FROM SALE OF ITS NEW JERSEY STATE NOLS IN Q4 OF 2018.SALE OF ITS NEW JERSEY STATE NOLS IS EXPECTED TO CONTRIBUTE TO FUNDING OPERATIONS INTO Q4 OF 2020.
Full Article
Jan 4 (Reuters) - Celsion Corp ::CELSION ANNOUNCES FDA CLEARANCE OF THE OVATION II STUDY FOR THE EVALUATION OF GEN-1 IMMUNOTHERAPY TO TREAT NEWLY DIAGNOSED STAGE III/IV OVARIAN CANCER.CELSION CORP - EXPECTS TO INITIATE ENROLLMENT OF PHASE I PORTION OF OVATION II STUDY IN FIRST HALF OF 2018.CELSION CORP - COMPANY EXPECTS TO HAVE 25% OF OVATION II STUDY ENROLLED BY END OF 2018.
Full Article
Nov 14 (Reuters) - Celsion Corp :Celsion Corporation reports third quarter 2017 financial results and provides business update.Q3 loss per share $0.70.
Full Article
Earnings vs. 
Estimates